Skip to main content
Skip to content
HOME
ABOUT
VBL
COMPANY OVERVIEW
MANAGEMENT TEAM
BOARD OF DIRECTORS
ADVISORY BOARDS
CANCER
PROGRAMS
CANCER PLATFORM & TECHNOLOGY
PUBLICATIONS
INFLAMMATION
PROGRAMS
INFLAMMATORY PLATFORM
INFLAMMATORY PIPELINE
PUBLICATIONS
VB-600
PLATFORM
OVERVIEW
TARGETING MOSPD2 FOR INFLAMMATION
TARGETING MOSPD2 FOR CANCER
PUBLICATIONS
PATIENTS &
CAREGIVERS
CLINICAL TRIALS
COMPASSIONATE USE
INVESTOR
RELATIONS
IR HOMEPAGE
PRESS RELEASES
EVENTS AND PRESENTATIONS
STOCK INFORMATION
ANALYST COVERAGE
CORPORATE GOVERNANCE
SEC FILINGS
INVESTOR FAQ & CONTACTS
PRESS RELEASES
PRESS RELEASE ARCHIVE
March 9, 2018
VBL Therapeutics to Report Fiscal 2017 Results on March 15
